EXPRESSION OF ESTROGEN RECEPTORS IN BREAST AS MOLECULAR MARKERS OF PROLIFERATION PROGRESSION

Introduction. Fibroadenomatosis (FAM) is a heterogeneous group of pathological conditions of the mo-Nochnoi gland, with hormone-dependent nature and different degree of risk maligni of the organization. The use of routine histological stains is not enough to determine the expectation of FAM, therefore, the development of immunohistochemical markers for assessing progression PHAM is a prospective problem of modern morphology. The aim of this work is to assess the possibility of using immunohistochemical method with ve-eficacia levels and types of estrogen receptors (ER) to determine the potential and Pro-activity operativnoi FAM. Methods. Material for the study consists of breast tissue obtained during surgery, about localized FAM and in the course of reduction-tion operations. According to the results of morphological studies was formed the following groups of the study. Group I – non-proliferative FEMME, group II – proliferation-tive FAM, group III – carcinoma in situ, developed on the background of nonproliferative FAM, IV groups– carcinoma in situ, developed on the background of proliferative FEMME, group V – control. Immunohistochemistry was performed using primary antibodies to estrogen receptor type alpha (Erα) type beta (ERβ) and progesterone receptors (PR). Evaluation of expression was performed in terms of relative area. Results. As a result of the work, the following results were obtained. In group I, the expression level of ERα was 5,9±1,8%, ERβ 9,6±2,3%, and PR 7,6±2,3%. In group II ERα, 5,4±1,7%, ERβ 4,4±1,6 and PR 3,6±1,3. When the groups were compared, a significant increase in ERβ expression in group I was found. When comparing the groups with the control group, where the level of expression of ERα was 5,8±1,5%, ERβ 8,7±2,2% and PR 5,6±1,4%, group I did not show any difference in II Group, the expression level of ERβ was lower by half. In carcinoma groups in situ, against the background of nonproliferative FAM, ERα was 2,02±1,5%, ERβ 4,3±1,7, PR 5,7±2,8, and against the background of ERα proliferation was 3,1±1,0%, ERβ 2,6±1,2 and PR 5,4±1,6. Comparison within the group revealed differences in the expression levels of both ERα and ERβ, the same differences were found in the comparison of groups III and IV with the control group. The ratio of study markers in the nonproliferative FAM and nonproliferative cancer groups demonstrates that with FAM, sufficiently high levels of both alpha and beta estrogen, which are not significantly different from normal, and in the tumor process, all estrogen receptors are downregulated and the same trend is traced And in groups of proliferative processes. At the same time for non-proliferative processes more revealing is the change in the expression of estrogen beta for the proliferative level of estrogen alpha. Conclusion. The results demonstrate the possibility of using the immunostochochemical method with an evaluation of estrogen receptor expression levels for the diagnosis and evaluation of the proliferative potential of breast tissue.